In short
SAR443579 is an investigational drug currently being studied in clinical trials for various blood cancers, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), high-risk myelodysplastic syndrome (HR-MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This article provides an overview of the ongoing research and potential benefits of SAR443579 for patients with these challenging conditions.
At a glance
- Drug Name
- SAR443579
- Administration
- Intravenous infusion
- Target Conditions
- Relapsed/refractory AML, B-ALL, HR-MDS, BPDCN
- Study Population
- Adults and children (1+ years old)
- Primary Objectives
- Determine MTD/MAD, assess anti-leukemic activity
- Secondary Objectives
- Safety profile, PK profile, immunogenicity, response rates
- Key Inclusion Criteria
- Specific diagnoses, relapsed/refractory disease, no available therapies
- Key Exclusion Criteria
- Certain medical conditions, recent transplants, pregnancy
- Primary Endpoints
- Incidence of DLTs, proportion of CR+CRi
- Secondary Endpoints
- RDE, adverse events, PK parameters, ADA incidence, response rates
What is SAR443579?
SAR443579 is an investigational drug currently being studied for the treatment of certain blood cancers. It is a new medication that is still in the early stages of research, specifically in what's called a "first-in-human" study. This means it's the first time the drug is being tested in people after initial laboratory research.
What conditions does SAR443579 treat?
SAR443579 is being investigated to treat several types of blood cancers and related conditions:
- Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, causing rapid growth of abnormal white blood cells.
- B-cell Acute Lymphoblastic Leukemia (B-ALL): A cancer of the blood and bone marrow that affects B lymphocytes, a type of white blood cell.
- High-Risk Myelodysplastic Syndrome (HR-MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells.
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A rare and aggressive type of blood cancer that affects a specific type of immune cells.
The drug is being studied in patients whose cancer has either come back after treatment (relapsed) or hasn't responded well to previous treatments (refractory).
How does SAR443579 work?
SAR443579 is designed to target a specific protein called CD123, which is found on the surface of certain cancer cells. While the exact mechanism isn't fully described in the available information, drugs that target CD123 typically work by helping the immune system recognize and attack cancer cells more effectively.
Current Clinical Trial
SAR443579 is currently being studied in a clinical trial. This trial is an "open-label, first-in-human, dose-escalation/expansion study". Here's what these terms mean:
- Open-label: Both the researchers and participants know which treatment is being given.
- First-in-human: This is the first time the drug is being tested in people.
- Dose-escalation: The study will test different doses of the drug to find the safest and most effective dose.
- Expansion: Once a safe dose is found, more participants will be added to further study the drug's effects.
Who can participate in the trial?
The trial is open to both adults and children with specific blood cancers. Key eligibility criteria include:
- Age: Participants must be at least 1 year old. Adults are defined as 12 years and older, while the pediatric arm includes ages 1 to 17.
- Diagnosis: Participants must have one of the blood cancers mentioned earlier (AML, B-ALL, HR-MDS, or BPDCN).
- Previous treatments: The cancer must have either relapsed or not responded well to previous treatments.
- Weight: Participants must weigh at least 10 kg (about 22 pounds).
There are also several factors that might prevent someone from participating, such as certain medical conditions or previous treatments.
What are the objectives of the trial?
The main goals of this clinical trial are:
- To determine the safest and most effective dose of SAR443579.
- To assess how well SAR443579 works against these blood cancers, particularly in patients with AML.
- To study how the drug behaves in the body (its pharmacokinetics).
- To evaluate the safety and side effects of the drug.
- To see if the body develops antibodies against the drug (immunogenicity).
Safety Considerations
As with any investigational drug, there may be unknown risks and side effects. The trial is designed with several safety measures in place:
- Careful monitoring of participants for any side effects or adverse reactions.
- Regular check-ups and tests to assess the participant's health status.
- A process to determine the safest dose of the drug before giving it to more participants.
It's important to note that this is an early-stage trial, and much is still unknown about SAR443579. Patients considering participation should discuss the potential risks and benefits thoroughly with their healthcare provider and the research team.